In a global, open-label, phase III trial, patients with unresectable HCC who had not been previously treated with systemic therapy were randomly assigned to receive either atezolizumab (targeting PD-L1) plus bevacizumab (targeting VEGF-A) or sorafenib. Here, VEGFA is linked to hepatocellular carcinoma.